lifestyle.cosmeticsurgeryinsider.com

Author: PreludeDx

PreludeDx Receives FDA Breakthrough Device Designation for AidaBREAST® – Early-Stage Invasive Breast Cancer Assay

April 29, 2026
PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer

March 12, 2026
PreludeDx Appoints MiMi Reyes as Senior Executive Management Team to Support Growth Initiatives

January 23, 2026
PreludeDx Announces First Independent Validation of AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer

December 10, 2025